Recent Investment Analysts’ Ratings Updates for Ironwood Pharmaceuticals (IRWD)

Ironwood Pharmaceuticals (NASDAQ: IRWD) recently received a number of ratings updates from brokerages and research firms:

• 1/5/2026 – Ironwood Pharmaceuticals was upgraded by analysts at Citigroup Inc. from a “market perform” rating to an “outperform” rating.
• 1/5/2026 – Ironwood Pharmaceuticals was upgraded by analysts at Craig Hallum from a “hold” rating to a “strong-buy” rating.
• 1/5/2026 – Ironwood Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $3.00 to $5.00. They now have an “equal weight” rating on the stock.
• 1/5/2026 – Ironwood Pharmaceuticals was upgraded by analysts at Citizens Jmp from a “market perform” rating to a “market outperform” rating. They now have a $8.00 price target on the stock.
• 1/1/2026 – Ironwood Pharmaceuticals was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/29/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Ironwood Pharmaceuticals had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.